ストックスクリーナーアプリを入手
34.92
6.23%
-2.32
アフターアワーズ：
34.92
前日終値:
$37.24
開ける：
$37
24時間の取引高:
74,441
Relative Volume:
0.74
時価総額：
$256.54M
収益：
-
当期純損益:
$-4.98M
株価収益率:
-26.50
EPS:
-1.3177
ネットキャッシュフロー:
$-3.85M
1週間 パフォーマンス:
-2.84%
1か月 パフォーマンス:
-6.26%
6か月 パフォーマンス:
+3,118%
1年 パフォーマンス:
+1,884%
1日の値動き範囲:
$34.50
$37.00
1週間の範囲:
$32.78
$37.54
52週間の値動き範囲:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
34.92 | 256.54M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-23 | 開始されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - The Manila Times
Can This CNS Drug Developer's Triple Conference Tour Spark Investor Interest? - StockTitan
How the (DRUG) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Issues Negative Estimate for DRUG Earnings - Defense World
H.C. Wainwright maintains $85 target on Bright Minds stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains $85 target on Bright Minds stock - Investing.com India
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences’ BMB-101: A Promising Contender in Serotonergic Epilepsy Treatment with Strong Market Potential - TipRanks
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS - MarketBeat
Bright Minds Biosciences Dramatic Surge Highlights the High-Stakes Nature of Biotech Investments - HPBL
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - Benzinga
Bright Minds Biosciences Shows Financial Improvement in Latest Report - TipRanks
When (DRUG) Moves Investors should Listen - Stock Traders Daily
SEC Form F-3 filed by Bright Minds Biosciences Inc. - Quantisnow
More Money In The Bank For Bright Minds Biosciences Insiders Who Divested CA$16m - Simply Wall St
How To Buy Bright Minds Biosciences Inc. Stock Online in February 2025 - Traders Union
Long Term Trading Analysis for (DRUG) - Stock Traders Daily
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Bright Minds Biosciences Appoints Stephen Collins, M.D., Ph.D., as Chief Medical Officer - citybiz
Bright Minds Biosciences (NASDAQ:DRUG) Releases Earnings Results - MarketBeat
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
(DRUG) Long Term Investment Analysis - Stock Traders Daily
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
(DRUG) Investment Analysis - Stock Traders Daily
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
Bright Minds Biosciences Inc (DRUG) 財務データ
収益
当期純利益
現金流量
EPS
Bright Minds Biosciences Inc (DRUG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% Owner |
Oct 15 '24 |
Buy |
5.53 |
372,591 |
2,061,574 |
825,000 |
| Cormorant Asset Management, LP | 10% Owner |
Oct 16 '24 |
Buy |
23.46 |
50,000 |
1,172,813 |
875,000 |
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):